Search tips
Search criteria 


Logo of ijpsychHomeCurrent issueInstructionsSubmit article
Indian J Psychiatry. 2003 Oct-Dec; 45(4): 234–238.
PMCID: PMC2952370

Olanzapine and fluoxetine combination in severe or resistant depression


Objective :

The purpose of this study was to investigate the efficacy and safety of Fixed Dose Combination (FDC) of olanzapine 5 mg and fluoxetine 20 mg in Indian patients with severe or treatment resistant depression.

Design :

This was an open, non-comparative study of seven weeks duration with an initial placebo run in period of one week.

Method :

One hundred and fifty three patients were enrolled. One hundred and forty-four patients completed the study as per protocol and 151 patients were safety evaluable. One hundred and eleven patients (77%) received one tablet of FDC of olanzapine 5 mg / fluoxetine 20 mg once daily for 6 weeks, in patients (14%), the dose was stepped up at the end of 2 weeks to 2 tablets of FDC of olanzapine 5 mg/ fluoxetine 20 mg once daily for a further 4 weeks and 13 patients (9%) required dose to be stepped up at the end of 4 weeks to 3 tablets of FDC of olanzapine 5 mg and fluoxetine 20 mg once daily for last 2 weeks.

Results :

One hundred and thirty four patients (93%) responded to FDC of olanzapine and fluoxetine therapy (a responder was defined as a patient with 50 % reduction over baseline in HDRS total score at the end of therapy).Statistically significant (p < 0.0001) reductions in HDRS total score, MADRS total score and CGI severity scores were seen with olanzapine/ fluoxetine combination. One hundred and four patients (72%) were remitters (HDRS total score of <7) after 6 weeks of therapy.

Adverse experiences were reported by thirty one patients (20.5%). Majority of them were mild in intensity. No serious adverse event was recorded with study therapy. Three patients were withdrawn from the therapy due to adverse event.

Conclusion :

Treatment with FDC of olanzapine 5 mg / fluoxetine 20 mg was highly effective and well tolerated in Indian patients with severe or treatment resistant depression.

Keywords: Olanzapine, Fluoxetine, Severe depression

Full Text

The Full Text of this article is available as a PDF (242K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Roose SP, Glassman AH, Walsh BT, Woodring S. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry. 1986 Mar;143(3):345–348. [PubMed]
  • Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am. 1996 Jun;19(2):371–386. [PubMed]
  • Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord. 1982 Sep;4(3):173–193. [PubMed]
  • Wolfersdorf M, Barg T, König F, Leibfarth M, Grünewald I. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry. 1995 Mar;28(2):56–60. [PubMed]
  • Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry. 1993 Sep;54(9):338–342. [PubMed]
  • Wolfersdorf M, König F, Straub R. Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol. Neuropsychobiology. 1994;29(4):189–193. [PubMed]
  • Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull. 1993;19(2):303–315. [PubMed]
  • Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am. 1993 Sep;16(3):589–610. [PubMed]
  • Tollefson GD, Beasley CM, Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997 Sep;154(9):1248–1254. [PubMed]
  • Tran PV, Dellva MA, Tollefson GD, Beasley CM, Jr, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry. 1997 May;58(5):205–211. [PubMed]
  • Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001 Jan;158(1):131–134. [PubMed]

Articles from Indian Journal of Psychiatry are provided here courtesy of Medknow Publications